LENSAR (NASDAQ:LNSR - Get Free Report) was downgraded by equities researchers at BTIG Research from a "strong-buy" rating to a "hold" rating in a research note issued on Monday, March 24th,Zacks.com reports.
Separately, Lake Street Capital reaffirmed a "hold" rating and set a $15.00 price objective (down from $16.00) on shares of LENSAR in a research report on Monday, March 24th.
View Our Latest Analysis on LNSR
LENSAR Price Performance
Shares of NASDAQ LNSR traded up $0.04 during trading hours on Monday, hitting $14.17. 92,218 shares of the stock were exchanged, compared to its average volume of 60,702. The firm has a market capitalization of $166.99 million, a P/E ratio of -9.70 and a beta of 0.62. LENSAR has a one year low of $2.67 and a one year high of $17.31. The company's 50 day moving average is $12.04 and its 200 day moving average is $8.52.
LENSAR (NASDAQ:LNSR - Get Free Report) last announced its earnings results on Thursday, February 27th. The company reported ($1.61) EPS for the quarter, missing the consensus estimate of ($0.21) by ($1.40). LENSAR had a negative return on equity of 49.02% and a negative net margin of 34.03%. The business had revenue of $16.73 million during the quarter, compared to analyst estimates of $14.95 million.
Institutional Investors Weigh In On LENSAR
A number of institutional investors and hedge funds have recently made changes to their positions in LNSR. Brandes Investment Partners LP lifted its holdings in LENSAR by 10.4% during the fourth quarter. Brandes Investment Partners LP now owns 489,318 shares of the company's stock worth $4,375,000 after acquiring an additional 45,920 shares during the period. Renaissance Technologies LLC grew its position in LENSAR by 13.3% during the fourth quarter. Renaissance Technologies LLC now owns 348,891 shares of the company's stock valued at $3,119,000 after buying an additional 40,946 shares during the period. Geode Capital Management LLC increased its holdings in LENSAR by 5.6% during the fourth quarter. Geode Capital Management LLC now owns 106,058 shares of the company's stock worth $948,000 after buying an additional 5,627 shares during the last quarter. Essex Investment Management Co. LLC raised its position in LENSAR by 18.3% in the fourth quarter. Essex Investment Management Co. LLC now owns 39,890 shares of the company's stock worth $357,000 after acquiring an additional 6,184 shares during the period. Finally, Atria Investments Inc grew its position in shares of LENSAR by 28.2% during the 4th quarter. Atria Investments Inc now owns 26,055 shares of the company's stock valued at $233,000 after acquiring an additional 5,729 shares during the period. Institutional investors and hedge funds own 40.15% of the company's stock.
LENSAR Company Profile
(
Get Free Report)
LENSAR, Inc, a commercial-stage medical device company, focuses on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. It offers LENSAR Laser System that incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, procedure planning, design, and precision.
Further Reading
Before you consider LENSAR, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and LENSAR wasn't on the list.
While LENSAR currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
